Amgen Inc. (NASDAQ:AMGN) Shares Sold by Whittier Trust Co.

Whittier Trust Co. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.3% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 35,180 shares of the medical research company’s stock after selling 123 shares during the period. Whittier Trust Co.’s holdings in Amgen were worth $9,169,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Swedbank AB raised its holdings in shares of Amgen by 1.1% in the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after purchasing an additional 5,751 shares in the last quarter. Quest Partners LLC increased its holdings in Amgen by 1,568.7% in the third quarter. Quest Partners LLC now owns 1,919 shares of the medical research company’s stock valued at $618,000 after buying an additional 1,804 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Amgen in the third quarter valued at $219,000. Payden & Rygel lifted its holdings in Amgen by 0.6% during the 3rd quarter. Payden & Rygel now owns 35,400 shares of the medical research company’s stock worth $11,406,000 after buying an additional 200 shares during the last quarter. Finally, Citizens Financial Group Inc. RI boosted its position in shares of Amgen by 4.4% during the 3rd quarter. Citizens Financial Group Inc. RI now owns 14,844 shares of the medical research company’s stock worth $4,783,000 after acquiring an additional 626 shares in the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Down 0.2 %

Shares of Amgen stock opened at $315.04 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The firm has a market cap of $169.24 billion, a price-to-earnings ratio of 41.73, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company’s 50-day simple moving average is $296.17 and its 200-day simple moving average is $299.14.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.02%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Analyst Ratings Changes

AMGN has been the subject of several recent analyst reports. UBS Group restated a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Truist Financial cut their price target on shares of Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research note on Wednesday, January 8th. Wells Fargo & Company restated an “equal weight” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, StockNews.com cut Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $314.04.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP David M. Reese sold 25,225 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the sale, the executive vice president now directly owns 36,922 shares in the company, valued at $11,240,533.68. This trade represents a 40.59 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 69,341 shares of company stock valued at $20,644,335. 0.69% of the stock is owned by company insiders.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.